GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Hosted on MSN17h
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Zacks.com on MSN17h
LLY Rises More Than 4% in a Week: How to Play the Stock
Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
7 Attractive Sectors For Growth Stocks In The Next Decade
Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...
Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just<a class="excerpt-read-more" href=" More ...
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
moneycontrol.com22h
Eli Lilly
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...